Fig. 8: Weight change following viral challenges.
From: Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2
A Intranasal challenge with influenza H1N1 virus (A/California/07/2009 (H1N1) x A/Puerto Rico/8/1934) at 103 TCID50/mL dose, on day 35 post prime immunization. B Intranasal challenge with 104 TCID50/mL SARS-CoV-2, mouse-adapted, MA10 Variant, on d42 post prime immunization. N = 5 per group.
